Survival in ovarian cancer in Wales: Prior to introduction of all Wales guidelines

International Journal of Gynecological Cancer

Volumn 16, Issue 5, 2006, Pages 1770-1776

  Shylasree, T S ^a   Howells, R E J ^a   Lim, K ^a   Jones, P W ^b   Fiander, A ^a   Adams, M ^c   Evans, A S ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Centralization of services; Ovarian cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL;

ADOLESCENT; ADULT; AGED; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA COLLECTION METHOD; DISEASE SEVERITY; FEMALE; HOSPITAL; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MEDICAL CARE; MEDICAL PARAMETERS; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; PATIENT CODING; PATIENT INFORMATION; PATIENT REFERRAL; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SURGEON; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PRACTICE GUIDELINES; REFERRAL AND CONSULTATION; WALES;

EID: 33749152326     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00653.x     Document Type: Review

References (30)

1. National Cancer Guidance Steering Group. Improving outcomes in gynaecological cancers: the manual. London: NHS Executive, Department of Health, 1999.
2. Wolfe CD, Tilling K, Raju KS. Management and survival of ovarian cancer patients in south east England. Eur J Cancer 1997;33:1835-40.
3. Tilling K, Wolfe CD, Raju KS. Variations in the management and survival of women with endometrial cancer in south east England. Eur J Gynaecol Oncol 1998;19:64-8.
4. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994;70:363-70.
5. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994;70:1014-7.
6. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993;72:3663-70.
7. Junor EJ, Hole DJ. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish National Study of 1866 patients. Br J Obstet Gynaecol 1999;106:1130-6.
8. Welsh Cancer Intelligence and Surveillance Unit. Cancer Registration and Survival in Wales 1985-1994. Cardiff: NHS Cymru Wales, 1995.
9. Cancer Services Co-ordinating Group. All Wales guidelines for the management of gynaecological cancers 2001. Cardiff: NHS Cymru Wales, 2001.
10. Woodman C, Baghdady A, Collins S, Clyma JA. What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol 1997;104:135-9.
11. Sengupta PS, Jayson GC, Slade RJ, Eardley A, Radford JA. An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br J Cancer 1999;80:444-7.
12. Allen DG, Baak J, Belpomme D et al. Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 1993;4(Suppl. 4):83-8.
13. Hudson CN, Potsides P, Curling OM. An audit of surgical treatment of ovarian cancer in a metropolitan health region. J R Soc Med 1991;84:206-9.
14. Voest EE, Van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival measured with the log (relative risk) as main objectives. Eur J Cancer Clin Oncol 1989;25(4):711-20.
15. McGowan L. Patterns of care in carcinoma of the ovary. Cancer 1993;71(Suppl. 2):628-33.
16. Mayer AR, Chambers SK, Graves E et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992;47:223-7.
17. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-11.
18. Marsoni S, Torri V, Valsecchi MG et al. Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 1990;62:444-50.
19. Heintz APM, Van Oosterom AT, Trimbos JBMC, Schaberg A, Van Der Velde EA, Nooy M. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 1988;30:347-58.
20. Farias-Eisner R, Oliveira M, Teng F, Berek J. The influence of tumor distribution number and size after optimal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 1992;46:267.
21. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
22. Burghardt E, Girardi F, lahousen M, Tamussino K, Stettener H. Patterns of pelvic and para-aortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991;40:103-6.
23. Wolfe CD, Tilling K, Bourne HM, Raju KS. Variations in the screening history and appropriateness of management of cervical cancer in south east England. Eur J Cancer 1996;32A:1198-204.
24. Jackson S, Murdoch J, Howe K, Bedford C, Sanders T., Prentice A The management of cervical carcinoma within the south west region of England. Expert tumour panel. Br J Obstet Gynaecol 1997;104:140-4.
25. National Institute for Clinical Excellence. Guidance on the use of taxanes for ovarian cancer. London: NHS Executive, Department of Health, 2000.
26. National Cancer Guidance Steering Group. Improving outcomes in gynaecological cancers: the research evidence. London: NHS Executive, Department of Health, 1999.
27. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479-87.
28. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
29. Du Bois A, Pfisterer J. Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl. 1):42-50.
30. Sandercock J, Parmar MK, Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78:1471-8.